Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Primary Myelofibrosis 1Polycythemia Vera 1Mesothelioma, Malignant 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

bintrafusp alfa protein, human 3Radiotherapy 3Cisplatin 3pembrolizumab 2Gemcitabine 2vactosertib 1fresolimumab 1fludarabine 1enzalutamide 1ascrinvacumab 1Trabedersen 1Temozolomide 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Paclitaxel 1Losartan 1Lomustine 1LY3300054 1LY-2157299 1Fenretinide 1Drug Delivery Systems 1Cyclophosphamide 1Carboplatin 1Bevacizumab 1Anastrozole 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × fresolimumab × Clear all
NCT01401062 2019-03-05

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

Weill Medical College of Cornell University

Phase 2 Completed
23 enrolled 8 charts
Breast

Breast Neoplasms, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡